2-hydroxy-heptanoic acid amide | 687-71-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-hydroxy-heptanoic acid amide
• 英文别名: 2-hydroxy-enanthic acid amide；2-Hydroxy-oenanthsaeure-amid；α-Oxy-oenanthsaeure-amid；2-Hydroxy-heptansaeure-amid；Heptanol-(2)-amid-(1)；Dioximinoheptan；2-hydroxyheptanamide
• CAS: 687-71-8
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: UASBPOOBTIHEPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-hydroxy-heptanoic acid amide 、 丙酮 在 硫酸 作用下， 反应 16.0h， 生成 2,2-dimethyl-5-pentyl-oxazolidin-4-one
  参考文献：
  名称：

  行为举止。4-恶唑酮。

  摘要：

  DOI：

  10.1021/jm00325a019
• 作为产物：
  描述：

  ethyl 2-hydroxylheptanoate 在 氨 作用下， 生成 2-hydroxy-heptanoic acid amide
  参考文献：
  名称：

  Helms, Chemische Berichte, 1875, vol. 8, p. 1168

  摘要：

  DOI：

文献信息

• [EN] SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY<br/>[FR] ISOSTÈRES DU SCRIPTAID ET LEUR UTILISATION EN THÉRAPIE
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2010086646A1

  公开（公告）日：2010-08-05

  Compounds of the invention are of the formula (I); wherein: … is a double bond and X is C; or … is a single bond and X is N, CH or CQR1; and wherein: n is 1 to 10; R is H or QR1; each R' is independently selected from H and QR1; each Q is independently selected from a bond, CO, NH, S, SO, SO2 or O; each R1 is independently selected from C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, substituted or unsubstituted aryl or heteroaryl, acyl, C1-C10 cycloalkyl, halogen, C1-C10 alkylaryl or C1-C10 heterocycloalkyl; L is a nitrogen-containing heteroaryl; and W is a zinc-chelating residue; or a pharmaceutically acceptable salt thereof. The compounds are useful in therapy.

  本发明的化合物具有公式(I)：其中：…表示双键，X为C；或…表示单键，X为N、CH或CQR1；并且：n为1至10；R为H或QR1；每个R'独立地选自H和QR1；每个Q独立地选自键、CO、NH、S、SO、SO2或O；每个R1独立地选自C1-C10烷基、C2-C10烯基、C2-C10炔基、取代或不取代的芳基或杂芳基、酰基、C1-C10环烷基、卤素、C1-C10烷基芳基或C1-C10杂环烷基；L是含有氮的杂芳基；W是锌螯合残基；或其药用可接受盐。这些化合物在治疗中有用。
• [EN] N-HYDROXY-7-(ARYLAMINO)HEPTANAMIDE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS<br/>[FR] DERIVES DE N-HYDROXY-7-(ARYLAMINO)HEPTANAMIDE UTILES POUR TRAITER DES MALADIES HYPERPROLIFERATIVES
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2004110989A1

  公开（公告）日：2004-12-23

  This invention relates to novel N-hydroxy-7-(arylamino)heptanamide derivative compounds including salts, carbonates and O-acylated derivatives thereof, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions for treating hyper-proliferative disorders.

  本发明涉及新型N-羟基-7-(芳基氨基)庚酰胺衍生物化合物，包括盐、碳酸盐和O-酰化衍生物，含有这些化合物的药物组合物，以及利用这些化合物或组合物治疗过度增殖性疾病的用途。
• Compounds having aromatic rings and side-chain amide-functionality and a method for transporting monovalent anions across biological membranes using the same
  申请人：Davis T. Jeffery

  公开号：US20050009921A1

  公开（公告）日：2005-01-13

  A compound containing at least two aromatic rings covalently bonded together, with each aromatic ring containing at least one oxyacetamide-based side chain, the compound being capable of forming a chloride ion channel across a lipid bilayer, and transporting chloride ion across the lipid bilayer.

  含有至少两个芳香环的化合物，这些芳香环以共价键结合在一起，每个芳香环至少含有一个氧乙酰胺基侧链，该化合物能够在脂质双分子层上形成氯离子通道，并在脂质双分子层上运输氯离子。
• 1-aryl-2-hydroxyethyl amides as potassium channel openers
  申请人：——

  公开号：US20040122007A1

  公开（公告）日：2004-06-24

  The present invention provides novel aryl hydroxyethyl amides and related derivatives having the general Formula I 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and A are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said aryl hydroxyethyl amides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.

  本发明提供了新型芳基羟乙基酰胺和相关衍生物，其具有一般式I1，其中R1、R2、R3、R4、R5、R6、R7和A如规范中所定义，或其无毒药物可接受的盐、溶剂或水合物，可作为KCNQ钾通道的开放剂或激活剂。本发明还提供了包括上述芳基羟乙基酰胺的药物组合物，以及治疗对KCNQ钾通道开放活性敏感的疾病的方法，例如偏头痛或偏头痛发作、双相障碍、癫痫、急性和慢性疼痛以及焦虑症。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：Déziel Robert

  公开号：US20110196147A1

  公开（公告）日：2011-08-11

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  本发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，本发明提供了公式（I）中Q、J、L和Z所定义的化合物。